PriceTargets.com logo

Krystal Biotech - KRYS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $134.00
  • Forecasted Upside: 10.82%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$120.92 As of 06/5/2023 01:39 PM ET
▼ -3.28 (-2.64%)

This chart shows the closing price for KRYS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Krystal Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KRYS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KRYS

Analyst Price Target is $134.00
▲ +10.82% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $134.00, with a high forecast of $148.00 and a low forecast of $118.00. The average price target represents a 10.82% upside from the last price of $120.92.

This chart shows the closing price for KRYS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Krystal Biotech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/10/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/6/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2023

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2023Stifel NicolausBoost Target$102.00 ➝ $145.00Low
5/22/2023GuggenheimBoost Target$101.00 ➝ $130.00Low
5/22/2023Chardan CapitalBoost Target$133.00 ➝ $148.00Low
5/22/2023HC WainwrightBoost Target$119.00 ➝ $139.00Low
5/21/2023Bank of AmericaBoost Target$105.00 ➝ $118.00Low
4/17/2023Stifel NicolausInitiated CoverageBuy$102.00Low
3/22/2023William BlairReiterated RatingOutperformLow
2/28/2023GuggenheimReiterated RatingBuy$101.00Low
2/28/2023Chardan CapitalReiterated RatingBuy$133.00Low
2/28/2023HC WainwrightReiterated RatingBuy$119.00Low
2/28/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$79.00 ➝ $124.00Low
11/7/2022Chardan CapitalBoost TargetBuy$130.00 ➝ $133.00Low
11/7/2022HC WainwrightBoost TargetBuy$107.00 ➝ $119.00Low
8/24/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$74.00Low
8/9/2022Chardan CapitalLower TargetBuy$137.00 ➝ $130.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$91.00 ➝ $78.00High
3/29/2022GuggenheimLower Target$114.00 ➝ $101.00High
3/1/2022The Goldman Sachs GroupLower TargetBuy$125.00 ➝ $93.00High
2/28/2022HC WainwrightLower TargetBuy$124.00 ➝ $107.00Low
1/18/2022Bank of AmericaInitiated CoverageBuy$110.00High
11/30/2021The Goldman Sachs GroupBoost TargetBuy$85.00 ➝ $125.00High
11/29/2021HC WainwrightBoost TargetPositive ➝ Buy$103.00 ➝ $124.00N/A
7/20/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$73.00 ➝ $90.00Medium
7/2/2021JonestradingReiterated RatingBuy$97.00Low
7/2/2021William BlairReiterated RatingBuyMedium
7/1/2021Chardan CapitalReiterated RatingBuyMedium
3/1/2021HC WainwrightBoost TargetBuy$84.00 ➝ $103.00Low
2/9/2021JonestradingInitiated CoverageBuy$97.00Low
1/8/2021HC WainwrightBoost TargetBuy$68.00 ➝ $84.00Medium
11/11/2020B. RileyReiterated RatingBuy$100.00Low
9/30/2020B. RileyInitiated CoverageBuyMedium
9/18/2020B. RileyInitiated CoverageBuy$100.00High
8/25/2020Chardan CapitalReiterated RatingBuy$115.00Low
8/19/2020Chardan CapitalBoost TargetBuy$100.00 ➝ $115.00High
8/10/2020HC WainwrightReiterated RatingBuy$68.00Medium
6/4/2020Evercore ISIInitiated CoverageOutperform$90.00High
5/8/2020Chardan CapitalReiterated RatingBuy$100.00High
5/4/2020HC WainwrightReiterated RatingBuy$68.00High
5/4/2020William BlairReiterated RatingBuyHigh
3/10/2020Chardan CapitalReiterated RatingBuy$100.00High
3/10/2020HC WainwrightBoost TargetBuy$59.00 ➝ $68.00High
1/30/2020Chardan CapitalReiterated RatingBuy$90.00Medium
11/5/2019CowenReiterated RatingBuyMedium
11/4/2019William BlairReiterated RatingBuyHigh
9/26/2019GuggenheimSet TargetBuy$81.00High
9/24/2019The Goldman Sachs GroupInitiated CoverageNeutral$60.00High
9/4/2019William BlairReiterated RatingBuyLow
9/4/2019HC WainwrightSet TargetBuy$59.00Low
8/15/2019CowenReiterated RatingBuyLow
8/6/2019HC WainwrightBoost TargetBuy ➝ Buy$56.00 ➝ $59.00High
6/25/2019GuggenheimBoost TargetBuy$48.00 ➝ $73.00High
6/24/2019HC WainwrightBoost TargetBuy ➝ Buy$38.00 ➝ $56.00High
6/24/2019Chardan CapitalBoost TargetBuy$57.50 ➝ $75.00High
6/24/2019William BlairReiterated RatingBuyHigh
5/30/2019GuggenheimInitiated CoverageBuy$31.57Medium
5/24/2019HC WainwrightBoost TargetBuy ➝ Positive$32.00 ➝ $38.00Low
5/6/2019William BlairReiterated RatingBuyLow
5/6/2019CowenReiterated RatingBuyHigh
3/29/2019Chardan CapitalReiterated RatingBuy$57.50High
3/29/2019HC WainwrightReiterated RatingBuy$32.00High
3/12/2019Chardan CapitalBoost TargetBuy$50.00 ➝ $57.50Low
1/15/2019HC WainwrightReiterated RatingBuy$32.00Low
12/19/2018Cantor FitzgeraldReiterated RatingBuy$34.00High
12/12/2018CowenInitiated CoverageOutperformLow
11/5/2018HC WainwrightReiterated RatingBuy$32.00Low
11/5/2018William BlairReiterated RatingBuyLow
10/15/2018HC WainwrightBoost TargetBuy ➝ Buy$32.00 ➝ $35.50High
10/15/2018Cantor FitzgeraldReiterated RatingBuy$35.00High
9/24/2018HC WainwrightInitiated CoverageBuy$32.00High
9/10/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$28.00High
8/6/2018Chardan CapitalReiterated RatingBuy$35.00High
8/6/2018William BlairInitiated CoverageBuyHigh
7/19/2018LADENBURG THALM/SH SHSet TargetBuy$23.00 ➝ $38.00High
7/10/2018William BlairInitiated CoverageOutperformHigh
6/28/2018Chardan CapitalInitiated CoverageBuy$35.00Medium
(Data available from 6/5/2018 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/7/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/7/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/6/2023
  • 5 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
2/5/2023
  • 9 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2023
  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2023
  • 18 very positive mentions
  • 43 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/5/2023

Current Sentiment

  • 18 very positive mentions
  • 43 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Krystal Biotech logo
Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company's wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. Krystal was founded by Krish Krishnan & Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Read More

Today's Range

Now: $120.92
Low: $120.46
High: $127.02

50 Day Range

MA: $92.01
Low: $78.48
High: $124.20

52 Week Range

Now: $120.92
Low: $49.17
High: $127.02

Volume

139,626 shs

Average Volume

240,260 shs

Market Capitalization

$3.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Krystal Biotech?

The following equities research analysts have issued stock ratings on Krystal Biotech in the last year: Bank of America Co., Chardan Capital, Guggenheim, HC Wainwright, Stifel Nicolaus, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for KRYS.

What is the current price target for Krystal Biotech?

6 Wall Street analysts have set twelve-month price targets for Krystal Biotech in the last year. Their average twelve-month price target is $134.00, suggesting a possible upside of 7.9%. Chardan Capital has the highest price target set, predicting KRYS will reach $148.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $118.00 for Krystal Biotech in the next year.
View the latest price targets for KRYS.

What is the current consensus analyst rating for Krystal Biotech?

Krystal Biotech currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KRYS will outperform the market and that investors should add to their positions of Krystal Biotech.
View the latest ratings for KRYS.

What other companies compete with Krystal Biotech?

Other companies that are similar to Krystal Biotech include Immunovant, Revolution Medicines, Ginkgo Bioworks, Beam Therapeutics and Vir Biotechnology. Learn More about companies similar to Krystal Biotech.

How do I contact Krystal Biotech's investor relations team?

Krystal Biotech's physical mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company's listed phone number is (412) 586-5830 and its investor relations email address is [email protected]. The official website for Krystal Biotech is www.krystalbio.com. Learn More about contacing Krystal Biotech investor relations.